Search | Clinical Trials Finder

Conditions: Dyslipidemia
Interventions: Evolocumab, Placebo, Background Statin Therapy; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 1,974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 134
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 123 more

Conditions: Hyperlipoproteinemia Type III
Interventions: torcetrapib/atorvastatin, atorvastatin, fenofibrate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 22
States / cities: Anaheim, California • Huntington Beach, California • Orange, California + 18 more

Conditions: Healthy
Interventions: Rosuvastatin, Atorvastatin, Simvastatin, Digoxin, Caffeine; Drug
Lead sponsor: Tobira Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cardiovascular Disease, Cerebrovascular Disorders
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years and older
Enrollment: 26,784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: HIV Infections
Interventions: Pravastatin sodium, Simvastatin, Atorvastatin calcium, Ritonavir, Nelfinavir mesylate, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2002
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 10 more

Conditions: Renal Insufficiency
Interventions: Midazolam oral solution, Dabigatran and pitavastatin oral solution, Atorvastatin and rosuvastatin oral solution, Rifampin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Alirocumab, Placebo, LMT; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years and older
Enrollment: 18,924 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 273
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 218 more

Conditions: Coronary Artery Disease, Atherosclerosis, Heart Attack
Interventions: Statin, Aspirin tablet, Nexlizet, LEQVIO, Vascepa, Jardiance, Colchicine; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Malignant Neoplasm
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Atorvastatin Calcium, Peripheral Blood Stem Cell Transplantation; Procedure · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Stanford, California • Denver, Colorado • Seattle, Washington

Conditions: Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
Interventions: Atorvastatin, Niacin, Colesevelam, Placebo Niacin, Placebo Colesevelam; Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years to 70 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Boise, Idaho • Seattle, Washington + 1 more

Conditions: Dyslipidemias
Interventions: LY3202328, Placebo, Atorvastatin, Simvastatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Miami, Florida • Lenexa, Kansas • Marlton, New Jersey + 1 more

Conditions: Peripheral Arterial Disease
Interventions: Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA); Drug · Behavioral · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 40 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cardiovascular Disease, Cardiomyopathy, Heart Disease, Myocardial Disease, Myocardial Ischemia
Interventions: Atorvastatin Calcium; Drug
Lead sponsor: Philip Binkley; Other
Eligibility: 18 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hypercholesterolemia
Interventions: REGN727(SAR236553); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Cincinnati, Ohio • Knoxville, Tennessee

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and stable statin therapy, Stable statin therapy; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 86
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 83 more

Conditions: Healthy Controls
Interventions: Atorvastatin, Pneumovax 23, Placebo (lactose pill); Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 40 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Colon Cancer, Precancerous Condition, Rectal Cancer
Interventions: oligofructose-enriched inulin, sulindac, placebo, atorvastatin calcium, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 40 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor, Thoracic Cancer, Thoracic Neoplasms
Interventions: Atorvastatin and Lisinopril, Placebo; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: San Diego, California • Bethesda, Maryland

Conditions: Hypercholesterolemia, LDL Cholesterol
Interventions: LGT209 50 mg, LGT209 300 mg, Placebo, Statins (atorvastatin or simvastatin); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Fort Myers, Florida • Miramar, Florida

Conditions: Hypercholesterolemia
Interventions: Atorvastatin 20 mg, AEGR-733 5 mg, AEGR-733 10 mg, Placebo, AEGR-733 5 mg + atorvastatin 20 mg, AEGR-733 10 mg + atorvastatin 20 mg; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Huntsville, Alabama • Jacksonville, Florida • Ocala, Florida + 12 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Atorvastatin, Placebo atorvastatin; Drug
Lead sponsor: Laura Schanberg; Other
Eligibility: 10 Years to 21 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hepatitis c
Interventions: pioglitazone (Actos), atorvastatin (Lipitor); Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: Atorvastatin, ALG-055009, Rosuvastatin; Drug
Lead sponsor: Aligos Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.

Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

Statin Therapy for Ischemic and Nonischemic Cardiomyopathy

Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin

Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia

The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23

Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy

Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins

AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia

Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)

Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba

A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)